(NASDAQ: BNTC) Benitec Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.15%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 70.54%.
Benitec Biopharma's earnings in 2026 is -$46,303,000.On average, 8 Wall Street analysts forecast BNTC's earnings for 2026 to be -$39,596,805, with the lowest BNTC earnings forecast at -$50,164,199, and the highest BNTC earnings forecast at -$34,989,889. On average, 8 Wall Street analysts forecast BNTC's earnings for 2027 to be -$48,075,455, with the lowest BNTC earnings forecast at -$53,530,923, and the highest BNTC earnings forecast at -$42,925,740.
In 2028, BNTC is forecast to generate -$23,828,166 in earnings, with the lowest earnings forecast at -$30,300,523 and the highest earnings forecast at -$16,593,143.